| Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical … JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ... The Lancet Global Health 2 (1), e23-e34, 2014 | 238 | 2014 |
| The impact and cost of scaling up GeneXpert MTB/RIF in South Africa G Meyer-Rath, K Schnippel, L Long, W MacLeod, I Sanne, W Stevens, ... PloS one 7 (5), e36966, 2012 | 204 | 2012 |
| HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making HIV Modelling Consortium Treatment as Prevention Editorial Writing Group PLoS Medicine 9 (7), e1001259, 2012 | 99 | 2012 |
| Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study K Kranzer, SD Lawn, G Meyer-Rath, A Vassall, E Raditlhalo, ... Public Library of Science 9 (8), e1001281, 2012 | 95 | 2012 |
| Scaling up Xpert MTB/RIF technology: the costs of laboratory‐ vs. clinic‐based roll‐out in South Africa K Schnippel, G Meyer‐Rath, L Long, W MacLeod, I Sanne, WS Stevens, ... Tropical Medicine & International Health 17 (9), 1142-1151, 2012 | 73 | 2012 |
| Changing the South African national antiretroviral therapy guidelines: the role of cost modelling G Meyer-Rath, LF Johnson, Y Pillay, M Blecher, AT Brennan, L Long, ... PLoS One 12 (10), e0186557, 2017 | 72 | 2017 |
| HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions G Meyer-Rath, M Over PLoS medicine 9 (7), e1001247, 2012 | 70 | 2012 |
| Attrition through multiple stages of pre-treatment and ART HIV care in South Africa MP Fox, K Shearer, M Maskew, G Meyer-Rath, K Clouse, I Sanne PLoS One 9 (10), e110252, 2014 | 69 | 2014 |
| Prospects for HIV control in South Africa: a model-based analysis LF Johnson, C Chiu, L Myer, MA Davies, RE Dorrington, LG Bekker, ... Global health action 9 (1), 30314, 2016 | 67 | 2016 |
| The per-patient costs of HIV services in South Africa: systematic review and application in the South African HIV investment case G Meyer-Rath, C van Rensburg, C Chiu, R Leuner, L Jamieson, S Cohen PloS one 14 (2), e0210497, 2019 | 56 | 2019 |
| Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa Y Jo, L Jamieson, I Edoka, L Long, S Silal, JRC Pulliam, H Moultrie, ... Open Forum Infectious Diseases 8 (3), ofab040, 2021 | 55 | 2021 |
| Evidence for scaling up HIV treatment in sub-Saharan Africa: a call for incorporating health system constraints E Mikkelsen, JAC Hontelez, MPM Jansen, T Bärnighausen, K Hauck, ... PLoS medicine 14 (2), e1002240, 2017 | 54 | 2017 |
| Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa G Meyer-Rath, AT Brennan, MP Fox, T Modisenyane, N Tshabangu, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (3), 322-328, 2013 | 53 | 2013 |
| Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness LF Johnson, C van Rensburg, C Govathson, G Meyer-Rath Scientific reports 9 (1), 12621, 2019 | 51 | 2019 |
| Diagnosing Xpert MTB/RIF-negative TB: Impact and cost of alternative algorithms for South Africa K Schnippel, G Meyer-Rath, L Long, WS Stevens, I Sanne, S Rosen South African Medical Journal 103 (2), 101-106, 2013 | 48 | 2013 |
| Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa CAB Pearson, SP Silal, MWZ Li, J Dushoff, BM Bolker, S Abbott, ... MedRxiv, 2021.12. 19.21268038, 2021 | 46 | 2021 |
| Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case G Meyer-Rath, C Van Rensburg, B Larson, L Jamieson, S Rosen PLoS One 12 (10), e0186496, 2017 | 43 | 2017 |
| Targeting the right interventions to the right people and places: the role of geospatial analysis in HIV program planning G Meyer-Rath, JB McGillen, DF Cuadros, TB Hallett, S Bhatt, N Wabiri, ... Aids 32 (8), 957-963, 2018 | 40 | 2018 |
| Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa K McCarthy, MF Chersich, J Vearey, G Meyer-Rath, A Jaffer, S Simpwalo, ... International journal of STD & AIDS 20 (12), 858-862, 2009 | 40 | 2009 |
| Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? C Chiu, LF Johnson, L Jamieson, BA Larson, G Meyer-Rath BMC Public Health 17, 1-9, 2017 | 36 | 2017 |
